PD-L1 inhibitor
This page covers all PD-L1 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PD-L1, PD-L1 (Programmed Death Ligand 1).
Targets
PD-L1 · PD-L1 (Programmed Death Ligand 1)
Marketed (4)
- Avelumab first-line maintenance · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Oncology
Avelumab is a human monoclonal antibody that blocks PD-L1, releasing immune cells from tumor-induced suppression to attack cancer cells. - Atezolizumab Injection [Tecentriq] · Nykode Therapeutics ASA · Oncology
Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity. - AB · GlaxoSmithKline · Oncology
AB is a monoclonal antibody that binds to and inhibits a specific molecular target to modulate immune or disease-related pathways. - Adebrelimab combined with SOX regimen · Yang Jianjun, PhD · Oncology
Adebrelimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with SOX chemotherapy (S-1 and oxaliplatin) for enhanced cytotoxic and immunological effects.
Phase 3 pipeline (67)
- IBI305 · Innovent Biologics (Suzhou) Co. Ltd. · Oncology
IBI305 is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses. - BCD-055 · Biocad · Oncology
BCD-055 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - BCD-085 Q2W · Biocad · Oncology
BCD-085 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - BCD-132 · Biocad · Oncology
BCD-132 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - CT-P16 · Celltrion · Oncology
CT-P16 is a monoclonal antibody that binds to and blocks programmed death ligand 1 (PD-L1), enhancing anti-tumor immune responses by releasing the inhibition of T cells. - BCD-178 · Biocad · Oncology
BCD-178 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - HX008 · Taizhou Hanzhong biomedical co. LTD · Oncology
HX008 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 to enhance anti-tumor immune responses. - CT-P42 · Celltrion · Oncology
CT-P42 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. - SHR-1501 for Injection · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Oncology
SHR-1501 is a recombinant human anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 and PD-1/B7-1, thereby releasing immune checkpoint inhibition and enhancing anti-tumor T-cell responses. - HLX13 · Shanghai Henlius Biotech · Oncology
HLX13 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - HLX11 · Shanghai Henlius Biotech · Oncology
HLX11 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - HLX15-IV · Shanghai Henlius Biotech · Oncology
HLX15-IV is a humanized monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - CS1001 monoclonal antibody · CStone Pharmaceuticals · Oncology
CS1001 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses. - SHR-1209 · Jiangsu HengRui Medicine Co., Ltd. · Oncology
SHR-1209 is a humanized monoclonal antibody that blocks the interaction between PD-L1 and its receptors (PD-1 and B7-1) to enhance anti-tumor immune responses. - A166 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Oncology
A166 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses. - Atezolizumab Injection · Federation Francophone de Cancerologie Digestive · Oncology
Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity. - BCD-085 Q4W · Biocad · Oncology
BCD-085 is a monoclonal antibody that blocks the PD-L1 checkpoint, enabling the immune system to recognize and attack cancer cells. - BCD-100 · Biocad · Oncology
BCD-100 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - BCD-057 · Biocad · Oncology
BCD-057 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - TQB2825 Injection · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Oncology
TQB2825 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. - MEDI4736 · MedImmune LLC · Oncology
MEDI4736 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses. - Durvalumab (Regimen 1) · AstraZeneca · Oncology
Durvalumab is a monoclonal antibody that blocks PD-L1, preventing tumor cells from evading immune attack and allowing T cells to recognize and kill cancer cells. - BCD-264 · Biocad · Oncology
BCD-264 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - 9MW0813 · Mabwell (Shanghai) Bioscience Co., Ltd. · Oncology
9MW0813 is a monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. - Hemay022+AI · Tianjin Hemay Pharmaceutical Co., Ltd · Oncology
Hemay022+AI is an anti-PD-L1 monoclonal antibody combined with an AI-optimized therapeutic approach to enhance immune checkpoint inhibition and anti-tumor immunity. - Avelumab Weekly · EMD Serono Research & Development Institute, Inc. · Oncology
Avelumab is a human monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors to reinvigorate anti-tumor immune responses. - Adjuvant durvalumab · ETOP IBCSG Partners Foundation · Oncology
Durvalumab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/PD-L2 on immune cells, thereby restoring anti-tumor immune responses. - CT-P53 · Celltrion · Oncology
CT-P53 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. - CT-P47 · Celltrion · Oncology
CT-P47 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. - CT-P17 · Celltrion · Oncology
CT-P17 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. - MHB088C for Injection · Qilu Pharmaceutical Co., Ltd. · Oncology
MHB088C is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1. - BCD-201 · Biocad · Oncology
BCD-201 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - HLX10 · Shanghai Henlius Biotech · Oncology
HLX10 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses. - GC1107 · Green Cross Corporation · Oncology
GC1107 is a monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from inhibiting T cell activation. - HBM9161 Injection (680mg) · Harbour BioMed (Guangzhou) Co. Ltd. · Oncology
HBM9161 is a monoclonal antibody that blocks the interaction between PD-L1 and its receptors to enhance anti-tumor immune responses. - HMI-115 · Hope Medicine (Nanjing) Co., Ltd · Oncology
HMI-115 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. - SHR-8068 injection · Shanghai Hengrui Pharmaceutical Co., Ltd. · Oncology
SHR-8068 is a humanized monoclonal antibody that targets and inhibits the PD-L1 checkpoint protein to enhance anti-tumor immune responses. - DAG181 · Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. · Oncology
DAG181 is a humanized monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the PD-1/PD-L1 checkpoint inhibition. - KL-A167 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Oncology
KL-A167 is a humanized monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1. - INS068 injection · Jiangsu HengRui Medicine Co., Ltd. · Oncology
INS068 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.
Phase 2 pipeline (2)
- ASC22 · Ascletis Pharmaceuticals Co., Ltd. · Oncology
ASC22 is a humanized monoclonal antibody that blocks the PD-L1 checkpoint, enhancing anti-tumor immune responses by preventing PD-L1 from binding to PD-1 and B7.1 on immune cells. - Anti-PD-L1 antibody atezolizumab · Gustave Roussy, Cancer Campus, Grand Paris · Oncology
Atezolizumab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer.